On the 26th, Tianye Group's 600,000 kilowatt power plant No. 2 cooling tower constructed by the second direct project department of Xinjiang Tianye Tai'an Construction Co., Ltd. successfully achieved the tower body capping. So far, the first “Bing Corps Thermal Power First Tower†with a height of 103 meters, a diameter of 85 meters, and a water surface area of ​​4,500 square meters has undergone 220 days of meticulous construction, and the main construction has been completed 36 days in advance, setting aside similar projects in China. New record of speed.
Larotinib (Vitrakvi / Larotrectinib) is the first oral tyrosine kinase inhibitor approved for the treatment of NTRK gene fusion solid tumors. It is suitable for all types of solid tumors, regardless of their original location. NTRK gene fusion is a kind of chromosomal abnormality, which is formed when NTRK gene combines with another unrelated gene, and then translates and produces abnormal TRK protein.
Larotrectinib Intermediates,Larotrectinib Intermediates Cas 1218935-60-4,Intermediates Of Larotrectinib Cas 1218935-60-4,Cas1363380-51-1 Intermediates Of Larotrectinib
Jinan Guoding Pharmaceutical Co.,Ltd , https://www.jnguodingpharma.com